Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at HC Wainwright

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $24.00 price target on the stock.

CMPX has been the topic of several other reports. Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 1st. Leerink Partners upgraded shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Jefferies Financial Group increased their target price on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. D. Boral Capital reiterated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Monday. Finally, Piper Sandler began coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $13.38.

Compass Therapeutics Price Performance

NASDAQ:CMPX remained flat at $1.75 during trading hours on Monday. 428,079 shares of the company were exchanged, compared to its average volume of 862,932. The stock has a market cap of $242.00 million, a P/E ratio of -4.73 and a beta of 1.40. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08. The stock has a 50 day moving average price of $2.37 and a 200-day moving average price of $2.10.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, sell-side analysts forecast that Compass Therapeutics will post -0.36 EPS for the current year.

Insider Buying and Selling

In related news, Director Carl L. Gordon sold 3,571,428 shares of the business’s stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jonathan Anderman acquired 20,000 shares of the company’s stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the acquisition, the insider now directly owns 21,000 shares of the company’s stock, valued at $32,340. The trade was a 2,000.00 % increase in their position. The disclosure for this purchase can be found here. 28.50% of the stock is owned by corporate insiders.

Institutional Trading of Compass Therapeutics

Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its stake in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after purchasing an additional 12,917 shares during the last quarter. Independent Advisor Alliance acquired a new stake in shares of Compass Therapeutics in the fourth quarter worth about $26,000. BNP Paribas Financial Markets bought a new stake in shares of Compass Therapeutics during the 4th quarter worth about $27,000. XTX Topco Ltd acquired a new position in shares of Compass Therapeutics during the 3rd quarter valued at about $37,000. Finally, Mariner LLC bought a new position in shares of Compass Therapeutics in the 4th quarter valued at approximately $30,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.